Related Experiment Video
Updated: Jun 2, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Severe Mycoplasma pneumoniae-associated mucositis treated with immunoglobulins
Silvia Bressan1, Teresa Mion, Barbara Andreola
1Department of Pediatrics, University of Padova, Italy. silvia.bressan.1@unipd.it
Unlabelled:
Mycoplasma pneumoniae-associated mucositis (MPAM), previously labelled as atypical Stevens-Johnson syndrome (SJS), SJS with minimal or no skin manifestations, is a rare non-respiratory manifestation of Mycoplasma pneumoniae infection. The nineteen cases described so far in children and young adults were characterized by a high male gender prevalence (16/19) and a good response to appropriate antibiotic treatment and supportive care in the majority of patients. We describe a case of MPAM in a previously healthy girl, who improved after a 0.5 g/kg daily dose of intravenous immunoglobulins (IVIG) for four consecutive days, after traditional therapy had failed.
Conclusion:
The successful treatment with IVIG described in this report suggests that, where appropriate antibiotic and supportive therapy fails to improve the clinical course of severe MPAM, IVIG treatment is worth considering.
Insights
Mycoplasma pneumoniae-associated mucositis (MPAM) is a rare condition. Intravenous immunoglobulin (IVIG) therapy proved effective for a severe case when traditional treatments failed, suggesting its potential use.
Area of Science:
- Infectious Diseases
- Dermatology
- Immunology
Background:
- Mycoplasma pneumoniae-associated mucositis (MPAM), a rare non-respiratory manifestation of Mycoplasma pneumoniae infection, was previously mislabeled as atypical Stevens-Johnson syndrome.
- Most reported cases occurred in male children and young adults, typically responding well to antibiotics and supportive care.
Observation:
- This report details a case of MPAM in a previously healthy female patient.
- The patient did not respond to conventional antibiotic and supportive treatments.
Findings:
- The patient showed significant improvement after receiving a four-day course of intravenous immunoglobulins (IVIG) at a dosage of 0.5 g/kg daily.
- This case highlights a successful alternative treatment for severe MPAM.
Implications:
- Intravenous immunoglobulin (IVIG) therapy should be considered for severe cases of Mycoplasma pneumoniae-associated mucositis (MPAM) that do not respond to standard antibiotic and supportive care.
- This finding expands treatment options for this rare condition.
